+40%

est. 2Y upside i

Healthcare

Rank

#2054

Sector

Biotechnology

Est. Liquidity

~2Y

Data Quality

Data: Medium

Natera (NTRA) is a publicly traded company — RSUs convert to freely tradeable NASDAQ shares after vesting, meaning equity liquidity is real and begins within roughly 12-18 months, not contingent on an IPO or acquisition.

Last updated: May 5, 2026

Bull (30%)+115%

Signatera secures broad Medicare coverage expansion and Prospera gains additional organ indications, sustaining 38-40% revenue CAGR to ~$4.5B by 2027; the 30% ongoing patent royalty award cements MRD IP leadership. P/S re-rates from 13x to 15x as the path to profitability clarifies, implying a ~$67B market cap — roughly 2.2x the current $30.2B.

Base (47%)+24%

Growth decelerates to 25-28% as reimbursement remains choppy and Guardant Health intensifies competition in oncology MRD, reaching ~$3.7B revenue by 2027. P/S compresses from 13x to 10x as biotech multiples normalize across the sector, implying a ~$37B market cap — roughly 24% above today's entry price.

Bear (23%)-23%

Unfavorable CMS reimbursement rulings or an adverse outcome in the active securities fraud class action caps growth at 10-12%, bringing 2027 revenue to ~$2.9B while litigation costs accelerate cash burn. P/S compresses to 8x amid broader biotech multiple contraction, implying ~$23B — approximately a 23% loss from current levels.

Est. time to liquidity~1.5 years

Preference Stack Risk

low

Funding Intensity

1%

Natera is publicly traded on NASDAQ; total disclosed funding of $152M represents just 0.5% of the $30.2B market cap, making preference stack mechanics effectively irrelevant for common shareholders receiving RSUs.

Dilution Risk

moderate

As a pre-profitability biotech with very high capital intensity, Natera may issue equity to fund operations or bolt-on acquisitions, and stock-based compensation at this employee count creates ongoing dilution headwind.

Secondary Liquidity

active

NTRA trades on NASDAQ with substantial daily volume — RSUs convert to freely tradeable shares upon vesting with no lock-up beyond standard insider trading blackout windows.

Other — 163 roles

View all 163 open roles at Natera →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Natera's data — designed to show you've done your homework.

  • 1

    “Natera just won a 30% ongoing patent royalty on MRD-related patents — how does leadership plan to leverage that IP position to defend against Guardant's Lunar assay in the oncology market, and does that royalty award change the competitive calculus materially?”

  • 2

    “With $2.3B in revenue and 64.7% gross margins, what are the two or three specific operational levers management is pulling to reach operating breakeven, and what is the internal timeline communicated to employees?”

  • 3

    “How does the RSU refresh cadence work here — given the stock's volatility from reimbursement and litigation headlines, is there a performance-based equity component or annual refresh grant that meaningfully changes total comp over a 4-year tenure?”

Community

Valuation Sentiment

Our model estimates +40% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.